You can access drug patent data online. Trained examiners review all patent applications for all industries. This is done at patent and trademark office. Pharmaceutical patent life is usually 11.7 years.
It is the time between market entry, to patent expiration.
Pharmaceutical patent litigation takes place under Hatch-Waxman Act. The generic drug manufacturer brings the product in the market before all patents. This is done according to the branded version of drug expire. This procedure was debated in the Congress.
Patent litigation happens in unexpired pharmaceutical patent. The lawsuit ends, if pharmaceutical patent expires during litigation. If you have to enforce unexpired pharma patent, then only lawsuit is filed.
According to drug patent data, out of 8259 generic applications filed between 1984 and 2001, only six percent raised patent issue. And, 94 per cent did not raise any patent issue. So, 7781 drug applications are not involved in Hatch-Waxman pharmaceutical patent litigation.
According to drug patent data, generics comprise of 19 percent of all prescriptions. Today, they account for half of the prescriptions. As per Wall Street data, the generic share in the market reached sixty percent by 2005. Only one-third of innovator drugs had generic copies.
Today, all top selling drugs with expired patent have generic competitors in market. Drug patent data shows that increased generic copies lead to erosion of branded drug market.
An economist at Columbia University, Mr. Frank, made a drug patent data, which suggests that new drugs save money as compared to old drugs. This increases the expense on the prescription drugs. It reduces non drug spending by 71 dollar. The net saving comes to 53 dollar.
The collection of exact yearly drug patent data is a must. This gives us regular updates in the pharma industry. This also avoids confusion in the later stages.
|